237 related articles for article (PubMed ID: 28091751)
1. Long-term treatment of Parkinson's disease with levodopa and other adjunctive drugs.
Mizuno Y; Shimoda S; Origasa H
J Neural Transm (Vienna); 2018 Jan; 125(1):35-43. PubMed ID: 28091751
[TBL] [Abstract][Full Text] [Related]
2. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
[TBL] [Abstract][Full Text] [Related]
3. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson's disease: a pilot study.
Liu G; Chen H; Su D; Wang D; Zhang M; Wang X; Wang Z; Yang Y; Jiang Y; Ma H; Feng T
Neurol Sci; 2020 Jan; 41(1):111-118. PubMed ID: 31446577
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.
Sato K; Hatano T; Yamashiro K; Kagohashi M; Nishioka K; Izawa N; Mochizuki H; Hattori N; Mori H; Mizuno Y;
Mov Disord; 2006 Sep; 21(9):1384-95. PubMed ID: 16763980
[TBL] [Abstract][Full Text] [Related]
5. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease.
Watts RL; Lyons KE; Pahwa R; Sethi K; Stern M; Hauser RA; Olanow W; Gray AM; Adams B; Earl NL;
Mov Disord; 2010 May; 25(7):858-66. PubMed ID: 20461803
[TBL] [Abstract][Full Text] [Related]
6. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
[TBL] [Abstract][Full Text] [Related]
7. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
[TBL] [Abstract][Full Text] [Related]
8. Optimising levodopa therapy for the management of Parkinson's disease.
Stocchi F
J Neurol; 2005 Oct; 252 Suppl 4():IV43-IV48. PubMed ID: 16222437
[TBL] [Abstract][Full Text] [Related]
9. [Multivariate analysis of the problems of long-term levodopa therapy in Parkinson's disease].
Nakamura Y; Yoshinaga J; Endo S; Hikiji A
Rinsho Shinkeigaku; 1997 Jun; 37(6):469-75. PubMed ID: 9366172
[TBL] [Abstract][Full Text] [Related]
10. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
Nicoletti A; Mostile G; Nicoletti G; Arabia G; Iliceto G; Lamberti P; Marconi R; Morgante L; Barone P; Quattrone A; Zappia M
J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
[TBL] [Abstract][Full Text] [Related]
11. [Problems of long-term levodopa therapy in Parkinson's disease].
Nakamura Y
Nihon Rinsho; 1997 Jan; 55(1):65-71. PubMed ID: 9014425
[TBL] [Abstract][Full Text] [Related]
12. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
[TBL] [Abstract][Full Text] [Related]
13. Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up.
Ogawa N; Kanazawa I; Kowa H; Kuno S; Mizuno Y; Tashiro K; Yanagisawa N
Eur Neurol; 1997; 38 Suppl 2():37-49. PubMed ID: 9387802
[TBL] [Abstract][Full Text] [Related]
14. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
[TBL] [Abstract][Full Text] [Related]
15. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
[TBL] [Abstract][Full Text] [Related]
16. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
[TBL] [Abstract][Full Text] [Related]
17. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
18. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
Stocchi F
Expert Opin Pharmacother; 2006 Jul; 7(10):1399-407. PubMed ID: 16805724
[TBL] [Abstract][Full Text] [Related]
19. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
[TBL] [Abstract][Full Text] [Related]
20. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
